Caption Management’s Soleno Therapeutics SLNO Stock Holding History

Caption Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$2.31M	–	2021
2025 Q4	$2.31M	Hold	50,000	–	–	0.02%	788
2025 Q3	$3.38M	Sell	50,000 -47,100	-49%	-$3.49M	0.03%	633
2025 Q2	$8.14M	Sell	97,100 -530,900	-85%	-$39.7M	0.09%	266
2025 Q1	$44.9M	Sell	628,000 -148,300	-19%	-$7.22M	0.43%	41
2024 Q4	$34.9M	Buy	776,300 +569,000	+274%	+$29.5M	0.33%	44
2024 Q3	$10.5M	Buy	+207,300	New	+$9.92M	0.17%	146
2020 Q3	–	Sell	-28,200	Closed	-$939K	–	1234
2020 Q2	$939K	Buy	+28,200	New	+$1.22M	0.03%	547

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Caption Management's SLNO Position: Q1 2026 in Review

Caption Management increased its Soleno Therapeutics (SLNO) stake by 898% in Q1 2026, buying an estimated $14.8M and bringing the position to 420,143 shares worth $14.1M. The position accounts for 0.08% of the portfolio, ranked #262.

Caption Management first reported a position in SLNO in Q1 2024 and has held it in 9 quarters since. The position peaked at $25M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Caption Management held 420,143 shares of Soleno Therapeutics worth $14.1M as of Q1 2026.
Caption Management bought 378,043 Soleno Therapeutics shares in Q1 2026, an estimated $14.8M.
Soleno Therapeutics made up 0.08% of Caption Management's portfolio in Q1 2026, its #262 holding.
Caption Management first reported a position in Soleno Therapeutics in Q1 2024 and has held it in 9 quarters since.
Caption Management's Soleno Therapeutics position peaked at $25M in Q3 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.